Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial
Authors
Keywords
-
Journal
EClinicalMedicine
Volume 53, Issue -, Pages 101649
Publisher
Elsevier BV
Online
2022-09-17
DOI
10.1016/j.eclinm.2022.101649
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of new‐onset type 2 diabetes in 600 055 people after COVID ‐19: A cohort study
- (2022) Morgan Birabaharan et al. DIABETES OBESITY & METABOLISM
- Inflammation in obesity, diabetes, and related disorders
- (2022) Theresa V. Rohm et al. IMMUNITY
- Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
- (2021) Norbert Stefan et al. Nature Reviews Endocrinology
- IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study
- (2021) Marco Franzetti et al. JOURNAL OF IMMUNOLOGY
- Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis
- (2021) Zixin Cai et al. BMC PUBLIC HEALTH
- Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
- (2021) Evdoxia Kyriazopoulou et al. NATURE MEDICINE
- Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study
- (2021) Min Gao et al. Lancet Diabetes & Endocrinology
- COVID-19, Hyperglycemia, and New-Onset Diabetes
- (2021) Kamlesh Khunti et al. DIABETES CARE
- Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
- (2021) Evdoxia Kyriazopoulou et al. Lancet Rheumatology
- Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
- (2020) Lihua Zhu et al. Cell Metabolism
- The Post-COVID-19 Functional Status (PCFS) Scale: a tool to measure functional status over time after COVID-19
- (2020) F.A. Klok et al. EUROPEAN RESPIRATORY JOURNAL
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study
- (2020) Naomi Holman et al. Lancet Diabetes & Endocrinology
- Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study
- (2020) Daniele Generali et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Blockage of interleukin-1β with canakinumab in patients with Covid-19
- (2020) Lorenza Landi et al. Scientific Reports
- Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure
- (2019) Brendan M. Everett et al. CIRCULATION
- IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes
- (2019) Piero Ruscitti et al. MEDICINE
- Inflammation in the pathophysiology and therapy of cardiometabolic disease
- (2019) Marc Y Donath et al. ENDOCRINE REVIEWS
- Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC
- (2019) Kam-Leung Siu et al. FASEB JOURNAL
- Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
- (2019) Piero Ruscitti et al. PLOS MEDICINE
- An Integrated View of Immunometabolism
- (2018) Yun Sok Lee et al. CELL
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
- (2018) Paul M Ridker et al. LANCET
- Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study
- (2018) Benjamin W. Van Tassell et al. CLINICAL CARDIOLOGY
- Inflammation, metaflammation and immunometabolic disorders
- (2017) Gökhan S. Hotamisligil NATURE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)
- (2015) Antonio Abbate et al. AMERICAN JOURNAL OF CARDIOLOGY
- Targeting inflammation in the treatment of type 2 diabetes: time to start
- (2014) Marc Y. Donath NATURE REVIEWS DRUG DISCOVERY
- Immunological Goings-on in Visceral Adipose Tissue
- (2013) Diane Mathis Cell Metabolism
- Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1 Antibody, in Patients With Type 2 Diabetes
- (2013) J. Sloan-Lancaster et al. DIABETES CARE
- Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
- (2012) C. Cavelti-Weder et al. DIABETES CARE
- Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial
- (2012) A. Rissanen et al. DIABETES OBESITY & METABOLISM
- The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
- (2011) S. J. Pocock et al. EUROPEAN HEART JOURNAL
- Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)
- (2010) Antonio Abbate et al. AMERICAN JOURNAL OF CARDIOLOGY
- Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes: The Whitehall II Study
- (2008) C. Herder et al. DIABETES CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now